Approval · Notice of Compliance 29626 · 2022
SOLIRIS: Notice of Compliance 29626
Issued December 5, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29626
- Date
- December 5, 2022
- Company
- Alexion Pharma GmbhBaar, --, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SOLIRIS | Not yet assigned | — |
Medicinal ingredients
- ECULIZUMAB 10 MG per ML